Schistosomiasis-associated pulmonary hypertension unveils disrupted murine gut–lung microbiome and reduced endoprotective Caveolin-1/BMPR2 expression

Ygor Marinho, Elizabeth S. Villarreal, Samuel Yaw Aboagye, David L. Williams, Jun Sun, Cláudia Lúcia Martins Silva, Sarah E. Lutz, Suellen D. OliveiraFrontiers in Immunology 2023 · DOI

This research paper, published in Frontiers in Immunology, explores the complex interplay between parasitic infection, the microbiome, and vascular health. It specifically investigates how the parasite Schistosoma mansoni triggers a deadly form of high blood pressure in the lungs.

TL;DR

Researchers have discovered that Schistosoma mansoni infection causes pulmonary arterial hypertension (PAH) by disrupting the "gut–lung microbiome axis" and depleting endoprotective proteins (Cav-1 and BMPR2) in lung endothelial cells. The study suggests that while parasite antigens trigger initial cellular stress, the resulting microbial dysbiosis may be a critical driver in shifting lung cells toward a pathological, disease-promoting state.

What Problem Does This Paper Address?

Pulmonary Arterial Hypertension (PAH) is a condition where the blood vessels in the lungs become thick and stiff, forcing the heart to work harder and eventually leading to heart failure. Schistosomiasis—a disease caused by parasitic flatworms—is a leading cause of PAH worldwide.

Scientists know that in PAH, the endothelial cells (ECs) lining the lung vessels become "apoptosis-resistant," meaning they don't die when they should and instead overgrow, clogging the vessels. Previous work identified two proteins, Caveolin-1 (Cav-1) and BMPR2, as vital "brakes" that prevent this overgrowth. However, the exact trigger that causes these proteins to disappear during a parasitic infection remained a mystery. Furthermore, while the gut microbiome's influence on systemic health is well-known, its specific "cross-talk" with the lung microbiome during infectious PAH was poorly understood.

Methods

The authors employed a multi-pronged approach using both animal models and human cell cultures:

  • In Vivo Murine Models: Mice were infected with S. mansoni (either via skin exposure to larvae or direct injection of eggs) to simulate chronic and acute disease.
  • Hemodynamic Assessment: The researchers measured right ventricular systolic pressure (RVSP) and heart hypertrophy to confirm the development of PAH.
  • Whole Metagenomic Sequencing (WGS): They performed WGS on both fecal pellets and lung tissue to map changes in the gut and lung microbiomes simultaneously.
  • In Vitro Cell Signaling: Human lung microvascular endothelial cells (HMVEC-L) were exposed to Sm-p40, the dominant antigen from S. mansoni eggs, to see if the antigen alone could replicate the disease's effects.
  • Lineage Tracing: They used specialized "Cre-Lox" mice to track how endothelial cells specifically lacking Cav-1 responded to the infection.

Datasets

The study generated and utilized several key datasets:

  • Metagenomic Data: Newly generated WGS data for murine lung and gut microbiomes under control and infected conditions (deposited in the NCBI Sequence Read Archive under BioProject ID PRJNA999692).
  • Microbial Classification: Used the One Codex Database, which contains ~127K complete microbial genomes, to identify shifts in bacterial and fungal populations.

Key Insights and Ideas

  • The Gut-Lung Axis is Real: Infection doesn't just stay in the gut or the blood; it fundamentally reshapes the microbial community of the lungs. Specifically, the researchers saw a significant drop in the phylum Ascomycota in the lungs of infected mice.
  • Loss of Endoprotection: S. mansoni eggs cause a dramatic reduction in Cav-1 and BMPR2. Without these proteins, the lung's vascular "defense system" collapses, allowing for the remodeling (thickening) of vessels.
  • The "Second Hit" Hypothesis: Interestingly, the egg antigen Sm-p40 did cause some cellular stress (phosphorylation of Cav-1) in the lab, but it was not enough to cause the full-scale cell death and protein shedding seen in live mice. This suggests that the parasite antigens are just the first step; the resulting disruption of the microbiome (dysbiosis) might be the "second hit" required to push the lungs into full-blown PAH.
  • Endothelial Vulnerability: Using genetic knockout models, the team showed that cells already lacking Cav-1 were significantly more susceptible to injury from the parasite, reinforcing Cav-1's role as a primary protector of lung health.

Key Results

  • Physiological Impact: Infected mice showed a significant increase in RVSP (blood pressure in the lungs) and right ventricular hypertrophy (heart thickening) compared to controls.
  • Vascular Remodeling: Microscopic analysis revealed significantly thicker microvessel walls in infected lungs, directly correlating with the loss of Cav-1 expression.
  • Microbiome Shifts: In the gut, infection increased the Firmicutes:Bacteroidetes ratio, a classic hallmark of systemic inflammation and dysbiosis. In the lungs, alpha-diversity (the variety of microbes) significantly decreased.
  • Molecular Signaling: The Sm-p40 antigen was shown to activate the TLR4/CD14 signaling pathway in human cells, providing a specific molecular target for potential future therapies.

Limitations and Future Work

While the study establishes a strong link between microbiome disruption and PAH, it primarily shows correlation. The authors acknowledge that more work is needed to prove causality—for example, by seeing if restoring a healthy microbiome can prevent or reverse the lung damage.

Future research will likely focus on identifying the specific "good" microbes that disappear during infection or the "bad" metabolites produced by a disrupted microbiome that travel from the gut to the lungs to cause injury. This could open the door for "pharmabiotics"—targeted microbial therapies to treat or prevent PAH in infected patients.

Summary updated

Abstract

Schistosomiasis-associated Pulmonary Arterial Hypertension (Sch-PAH) is a life-threatening complication of chronic <i>S. mansoni</i> infection that can lead to heart failure and death. During PAH, the expansion of apoptosis-resistant endothelial cells (ECs) has been extensively reported; however, therapeutic approaches to prevent the progression or reversal of this pathological phenotype remain clinically challenging. Previously, we showed that depletion of the anti-apoptotic protein Caveolin-1 (Cav-1) by shedding extracellular vesicles contributes to shifting endoprotective bone morphogenetic protein receptor 2 (BMPR2) towards transforming growth factor beta (TGF-β)-mediated survival of an abnormal EC phenotype. However, the mechanism underlying the reduced endoprotection in PAH remains unclear. Interestingly, recent findings indicate that, similar to the gut, healthy human lungs are populated by diverse microbiota, and their composition depends significantly on intrinsic and extrinsic host factors, including infection. Despite the current knowledge that the disruption of the gut microbiome contributes to the development of PAH, the role of the lung microbiome remains unclear. Thus, using a preclinical animal model of Sch-PAH, we tested whether <i>S. mansoni</i> infection alters the gut-lung microbiome composition and causes EC injury, initiating the expansion of an abnormal EC phenotype observed in PAH. Indeed, <i>in vivo</i> stimulation with <i>S. mansoni</i> eggs significantly altered the gut-lung microbiome profile, in addition to promoting injury to the lung vasculature, characterized by increased apoptotic markers and loss of endoprotective expression of lung Cav-1 and BMPR2. Moreover, <i>S. mansoni</i> egg stimulus induced severe pulmonary vascular remodeling, leading to elevated right ventricular systolic pressure and hypertrophy, characteristic of PAH. <i>In vitro</i>, exposure to the immunodominant <i>S. mansoni</i> egg antigen p40 activated TLR4/CD14-mediated transient phosphorylation of Cav-1 at Tyr14 in human lung microvascular EC (HMVEC-L), culminating in a mild reduction of Cav-1 expression, but failed to promote death and shedding of extracellular vesicles observed <i>in vivo</i>. Altogether, these data suggest that disruption of the host-associated gut-lung microbiota may be essential for the emergence and expansion of the abnormal lung endothelial phenotype observed in PAH, in addition to <i>S. mansoni</i> eggs and antigens.
BibTeX
@inproceedings{marinho2023schistosomiasis,
  author = {Ygor Marinho and Elizabeth S. Villarreal and Samuel Yaw Aboagye and David L. Williams and Jun Sun and Cláudia Lúcia Martins Silva and Sarah E. Lutz and Suellen D. Oliveira},
  title = {{Schistosomiasis-associated pulmonary hypertension unveils disrupted murine gut–lung microbiome and reduced endoprotective Caveolin-1/BMPR2 expression}},
  booktitle = {Frontiers in Immunology},
  year = {2023},
  doi = {10.3389/fimmu.2023.1254762},
}
Figure